TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31659242
Drug: Cinnamon supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon supplementation (3g daily)
Study: 31659242
Drug: Placebo (3g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3g daily)
Study: 27932411
Drug: MOD-4023 (once-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOD-4023 (once-weekly dosing at 18.5%, 37%, 55.5%, or 123.4% of individual cumulative weekly molar hGH dose)
Study: 27932411
Drug: MOD-4023 (once-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOD-4023 (once-weekly dosing at 61.7% molar hGH content during Stage B)
Study: 27932411
Drug: MOD-4023 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOD-4023 (various dosing cohorts)
Study: 23441963
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg extract Sceletium tortuosum (Zembrin)
Study: 23441963
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg extract Sceletium tortuosum (Zembrin)
Study: 19416039
Drug: Modafinil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (100 mg/d during weeks 1-2, 200 mg during weeks 3-4)
Study: 7800355
Drug: Treatment groups
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment groups (specific treatments not detailed in the abstract)
Study: 3279747
Drug: Sucrose (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (120 g)
Study: 3279747
Drug: Starch (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch (120 g)
Study: 11391261
Drug: Amoxicillin‐clavulanate potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin‐clavulanate potassium (2-week course)
Study: 9404747
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ipratropium bromide (IB) and albuterol sulfate (ALB)
Study: 9404747
Drug: Albuterol sulfate
Normalized name: Albuterol Sulfate
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol sulfate (ALB)
Study: 3055923
Drug: Lovastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20 mg twice daily)
Study: 27090436
Drug: Statin prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin prescription
Study: 12810502
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of alefacept
Study: 12810502
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of alefacept
Study: 10021470
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment (0.3 mg per kilogram of body weight per week) for 2 to 10 years
Study: 8672321
Drug: IL-1 receptor
Normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-1 receptor antagonist (IL-1ra) and TNF soluble receptors (TNFsr)
Study: 8672321
Drug: Granulocyte adhesion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte adhesion molecule expression
Study: 8672321
Drug: Fentanyl 175
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 175 micrograms with heparin 1050 u
Study: 8672321
Drug: Heparin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin alone 1050 u
Study: 1981223
Drug: Dipyridamole (DP)
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipyridamole (DP) 50 mg 3 times a day
Study: 1981223
Drug: ASA 300
Normalized name: ASA 300 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA 300 mg once a day
Study: 1981223
Drug: ASA 300
Normalized name: ASA 300 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA 300 mg once in combination with DP 50 mg 3 times a day
Study: 1981223
Drug: ASA 100
Normalized name: ASA 100 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA 100 mg once a day
Study: 1981223
Drug: ASA3 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA3 group (combined ASA 300 mg and ASADP groups)
Study: 27787547
Drug: Girentuximab (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Girentuximab (50 mg loading dose followed by 20 mg weekly for 24 weeks)
Study: 25556383
Drug: N-acetylcysteine (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (1200 mg/day)
Study: 21439642
Drug: povidone iodine
Normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: povidone iodine 2.5% solution
Study: 21439642
Drug: tetracycline 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: tetracycline 1% ointment
Study: 18201138
Drug: Brimonidine tartrate
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine tartrate 0.2% twice-daily
Study: 12898792
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (Andriol) 160 mg/day for 3 months
Study: 10534261
Drug: Vigabatrin (VGB)
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vigabatrin (VGB) at a target dose of 50 mg/kg
Study: 1746428
Drug: Enalapril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (2.5 mg orally at baseline and again 12 hours later)
Study: 15220229
Drug: Antimicrobial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial therapy for UTI
Study: 11821986
Drug: 1% aqueous
Normalized name: Zotane-HC 0.1%-1%-1% Aqueous Otic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% aqueous solution of poloxamine 1107 (treated)
Study: 2758540
Drug: Neostigmine 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.04 mg.kg‐1 with varying doses of atropine (0.014 to 0.04 mg.kg‐1) in Group A
Study: 2758540
Drug: Neostigmine 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.06 mg.kg‐1 with varying doses of atropine (0.02 to 0.04 mg.kg‐1) in Group B
Study: 900826
Drug: 5000 units
Normalized name: A-25, 25000 units oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 units of subcutaneous heparin 2 hr before the operation, then 5000 units 3 times daily for 6 days
Study: 900826
Drug: 5000 units
Normalized name: A-25, 25000 units oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 units of subcutaneous heparin
Study: 19622685
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg nefiracetam per day
Study: 19622685
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg nefiracetam per day
Study: 16536342
Drug: Self-etching adhesives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-etching adhesives (AdheSE, Adper Prompt L-Pop, Clearfil SE Bond, iBond, OptiBond Solo Plus - Self-Etch Adhesive System, Xeno III)
Study: 14641263
Drug: Levofloxacin 0.5%
Normalized name: LEVOFLOXACIN 0.5% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 0.5% eye drops, one drop every 15 min for four doses prior to surgery
Study: 14641263
Drug: Ciprofloxacin 0.3%
Normalized name: Ciprofloxacin 0.3%, Fluocinolone Acetonide 0.025% Otic drops, solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 0.3% eye drops, one drop every 15 min for four doses prior to surgery
Study: 9373657
Drug: Artesunate (intramuscular)
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate (intramuscular)
Study: 1554153
Drug: Deproteinized hemodialysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deproteinized hemodialysate 20% for infusion, 20 intra-arterial infusions over 4 weeks
Study: 1554153
Drug: Bencyclan 250
Normalized name: bencyclane
DrugBank: Bencyclane (DB13488)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bencyclan 250 mg in 250 mL saline 0.9%, 20 intra-arterial infusions over 4 weeks
Study: 1554153
Drug: Deproteinized hemodialysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deproteinized hemodialysate 20% for infusion
Study: 29704456
Drug: 0.05% tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% tretinoin cream applied three nights a week
Study: 27930530
Drug: Remifentanil (infused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (infused at 0.1 μg/kg/min and demand boluses of 0.1 μg/kg)
Study: 21732113
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) at 830 nm, 86 mW, 92.1 J/cm², 0.25 J, 3 s/point, at 20 points, repeated every 48 hours for 14 days
Study: 19099235
Drug: Dual release
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual release tablet (DRT-1) 300 mg
Study: 19099235
Drug: Conventional immediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immediate release tablet (Daxfen, 300 mg)
Study: 2132274
Drug: Chewable tablets
Normalized name: Pepcix Chewable Tablets
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chewable tablets containing pyridoxine and heat killed lactic bacteria
Study: 513885
Drug: Self-administered health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered health history questionnaire (SAHHQ)
Study: 6278914
Drug: Prolonged small
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged small dose propranolol (30 mg daily for 2 weeks)
Study: 6278914
Drug: Serial dose
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serial dose reduction of propranolol (for 6 to 9 days)
Study: 6278914
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy (for 2 additional weeks after dose reduction)
Study: 6278914
Drug: Prolonged small
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged small dose propranolol (30 mg daily)
Study: 31359178
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g IA‐TXA
Study: 31359178
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg IA‐TXA
Study: 23272227
Drug: artesunate monotherapy
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: artesunate monotherapy (2 mg/kg/day)
Study: 23272227
Drug: artesunate monotherapy
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: artesunate monotherapy (4 mg/kg/day)
Study: 23272227
Drug: artesunate monotherapy
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: artesunate monotherapy (2 mg/kg/day) and (4 mg/kg/day)
Study: 9869669
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (3 cycles of cisplatin and fluorouracil, followed by 2 additional cycles after surgery)
Study: 7613890
Drug: Metronidazole 500
Normalized name: metronidazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 500 mg intravenously 2 h before surgery
Study: 2529072
Drug: Epidural sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural sufentanil 30, 50, or 75 micrograms per dose in 20 ml normal saline solution
Study: 24154513
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol 250/50 µg, twice daily
Study: 24154513
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 µg, twice daily
Study: 19394976
Drug: pioglitazone +
Approvals — FDA: no, EMA: no, PMDA: no
Description: pioglitazone + metformin
Study: 24874591
Drug: glimepiride +
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: glimepiride + metformin
Study: 9483810
Drug: Ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinyl estradiol (0.03 mg) plus dienogest (2 mg)
Study: 9483810
Drug: Dienogest alone
Normalized name: Dienogest
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dienogest alone (0.5-2 mg/day)
Study: 9483810
Drug: Sequential regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential regimen of dienogest, chlormadinone acetate, and desogestrel
Study: 8141827
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid (5-ASA, mesalazine) 500 mg tid in slow release tablets (Salofalk)
Study: 8141827
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid (5-ASA, mesalazine) 250 mg in slow release tablets (Salofalk)
Study: 3707796
Drug: Morphine 2
Normalized name: apomorphine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 2 mg with adrenaline 50 micrograms
Study: 3707796
Drug: Morphine 2
Normalized name: apomorphine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 2 mg without adrenaline (plain morphine)
Study: 30782172
Drug: Placebo (informed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (informed that the capsule contained caffeine)
Study: 29157808
Drug: Saffron (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron (15 mg/Bid)
Study: 21704300
Drug: Preoperative β‐blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative β‐blockers
Study: 21704300
Drug: No preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preoperative β‐blockers
Study: 16838611
Drug: KTP-Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: KTP-Laser treatment
Study: 16838611
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (KTP-Laser + low-pressure TURP)
Study: 12883779
Drug: Antiresorptive and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiresorptive and osteoanabolic drugs for osteoporosis treatment
Study: 12883779
Drug: Treatment instituted
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment instituted during hospitalisation
Study: 12883779
Drug: Continued treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued treatment monitored by family doctor
Study: 11253344
Drug: High fixed
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fixed doses of unfractionated heparin
Study: 11253344
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of unfractionated heparin
Study: 1320907
Drug: Intravenous granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous granisetron (40 micrograms/kg)
Study: 1320907
Drug: Alizapride (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alizapride (4 mg/kg followed by 4 mg/kg at 4 and 8 h post-treatment) plus dexamethasone (8 mg)
Study: 29855986
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract EGb 761® (120 mg, twice a day)
Study: 29855986
Drug: Pentoxifylline (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (600 mg, twice a day)
Study: 24585444
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of green tea (200 mL of 1.5%, w/v)
Study: 24585444
Drug: Regular intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular intake of green tea (2 × 200 mL 1%, w/v per day for 7 days)
Study: 24585444
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of green tea
Study: 20808589
Drug: Immediate physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate physical therapy group (n = 16)
Study: 20808589
Drug: Delayed physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed physical therapy group (n = 15)
Study: 16103667
Drug: Granisetron +
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron + Alprazolam (G+A)
Study: 16103667
Drug: Granisetron alone
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron alone (G)
Study: 12186662
Drug: Diet history
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet history interviews and three‐day weighed food records administered at one‐month intervals in trial 1
Study: 12186662
Drug: Diet history
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet history interviews and three‐day weighed food records administered at three‐month intervals in trial 2
Study: 6376235
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Trestatin
Study: 6376235
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Trestatin
Study: 6376235
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Trestatin
Study: 6376235
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Trestatin
Study: 6376235
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Trestatin (diabetic patients)
Study: 6376235
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Trestatin (diabetic patients)
Study: 30741623
Drug: Edaravone therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone therapy
Study: 30741623
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no edaravone therapy)
Study: 26598090
Drug: Acarbose 100
Normalized name: acarbose 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 100 mg 3 times/day
Study: 23491928
Drug: Postoperative intravenous
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative intravenous SAMe treatment (1,000mg for seven days)
Study: 23491928
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standardized treatment)
Study: 23491928
Drug: Postoperative intravenous
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative intravenous SAMe treatment
Study: 21652619
Drug: Darunavir/ritonavir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir monotherapy (800/100 mg once daily)
Study: 20002740
Drug: Xeomin® treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xeomin® treatment
Study: 16440533
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate hydrofluoroalkane inhalation aerosol, 88 microg twice daily
Study: 16440533
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate hydrofluoroalkane inhalation aerosol, 220 microg twice daily
Study: 16440533
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate hydrofluoroalkane inhalation aerosol, 440 microg twice daily
Study: 16440533
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate hydrofluoroalkane inhalation aerosol (all doses)
Study: 11386892
Drug: Fenfluramine hydrochloride
Normalized name: fenfluramine hydrochloride
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine hydrochloride (60 mg daily)
Study: 9362431
Drug: Chemotherapy (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (standard combination regimens such as cyclophosphamide, methotrexate, and 5-fluorouracil; cyclophosphamide, doxorubicin, and 5-fluorouracil; mitoxantrone and 5-FU; single agents including paclitaxel and docetaxel)
Study: 9362431
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy (aminoglutethimide, medroxyprogesterone acetate, tamoxifen, newer aromatase inhibitors such as anastrozole, fadrozole, and letrozole, megestrol acetate)
Study: 1382676
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of zolpidem (Stilnox)
Study: 25940151
Drug: PPI therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI therapy for 5 weeks after endoscopic resection (ER)
Study: 18586835
Drug: FLGTN-HUT (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLGTN-HUT (800 mcg, metred spray)
Study: 11844897
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 900 mg and metoclopramide 10 mg
Study: 2314351
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion of prostaglandin E1
Study: 2314351
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion of buflomedil
Study: 2314351
Drug: Control conditions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control conditions (no infusion)
Study: 476231
Drug: Dopamine-beta-hydroxylase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine-beta-hydroxylase inhibitor (fusaric acid) combined with L-dopa (500 mg)
Study: 6407052
Drug: L-dopa alone
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa alone
Study: 15562885
Drug: Loratadine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (10 mg daily for 4 days)